UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13D/A
Under the Securities Exchange Act of 1934
(Amendment No. 1)
PHARMA-BIO SERV, INC.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
71711N100
(CUSIP Number)
Rebecca Baum
730 FIFTH AVENUE, 25TH FLOOR
NEW YORK, NY 10019
212-359-0200
(Name, Address and Telephone Number of Person Authorized to Receive Notices
and Communications)
February 22, 2007
 (Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G  to
report  the  acquisition that is  the  subject  of  this Schedule  13D, and
is filing this schedule because of  240.13d1(e), 240.13d-1(f) or 240.13d-
1(g), check the following box. [ ] Note:  Schedules  filed in paper format
shall  include  a  signed original and five copies of the schedule,
including all exhibits. See 240.13d-7 for other parties to whom copies are
to be sent.
*  The  remainder of this cover page shall be filled  out  for  a reporting
person's initial filing on this form with  respect  to the subject class of
securities, and for any subsequent amendment containing information which
would alter disclosures provided  in a prior cover page.
The  information  required on the remainder of  this  cover  page shall
not be deemed to be "filed" for the purpose of Section  18 of  the
Securities  Exchange Act of 1934  ("Act")  or  otherwise subject  to the
liabilities of that section of the Act but shall be  subject to all other
provisions of the Act (however, see  the Notes).

CUSIP NONE
13D
1	Name of Reporting Person
	Barron Partners LP
	I.R.S. Identification No. of Above Person
	431981699
2	Check the Appropriate Box if a Member of a Group  (a)  [ ]
	(b)  [  x ]
3	SEC Use Only
4	Source of Funds
	WC


5	Check Box if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e)
	 [    ]
6	Citizenship or Place of Organization
	Delaware
Number of		7	Sole Voting Power
Shares
Owned			   	3,979,174 shares
By Each		8	Shared Voting Power
Reporting			0
Person With
			9	Sole Dispositive Power
				3,979,174 shares
10	Shared Dispositive Power
	0
11	Aggregate Amount Beneficially Owned by Each Reporting Person
3,979,174
12	Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
	[      ]
13	Percent of Class Represented by Amount in Row (11)
	18.97%
14	Type of Reporting Person
	PN

Item 1.   Security and Issuer.
This statement relates to shares of common stock, par value $0.0001 per
share, (the "Common Stock") of Pharma-Bio Serv, Inc. a Delaware corporation
(the "Company") having its principal executive offices at Sardinera Beach
Building Suite 2,Marginal Costa de Oro, Dorado, Puerto Rico 00646.

Item 2.   Identity and Background.
This Statement is filed by Barron Partners LP, a Delaware Limited
Partnership (the "Reporting Person"), whose business address is 730 Fifth
Avenue, 25th Floor, New York, NY 10019.   The Reporting Person is
principally engaged in making investments.



The General Partner of the Reporting Person is Barron Capital Advisors LLC,
a Delaware Limited Liability Company, (the "General Partner").  Andrew
Barron Worden is the managing member of the General Partner.

During the last five years, to the best knowledge of the Reporting Person,
neither the Reporting Person nor any controlling person of the Reporting


Person has (i) been convicted in a criminal proceeding, or (ii) been a
party to a civil proceeding of a judicial or administrative body of
competent jurisdiction and as a result of such proceeding was or is subject
to a judgment, decree or final order enjoining future violations of, or
prohibiting or mandating activities subject to, Federal or State securities
laws or finding any violation with respect to such laws.

Item 3.   Source and Amount of Funds or Other Consideration.

N/A

Item 4.   Purpose of Transaction.
N/A


Item 5.   Interest in Securities of the Issuer.

(c)	Between February 22, 2007 and February 27, 2007 the Reporting Person
sold an aggregate of 8,077 shares of the Common Stock in open market
transactions at prices ranging from $1.01 to $1.02 per share.


Item 6.	Contracts, Arrangements, Understandings or


Relationships with Respect to Securities of the Issuer.
	Not applicable.

Item 7.	Material to be Filed as Exhibits.
	Not applicable.


SIGNATURE1
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.

Date: February 28th, 2007



/s/		ANDREW B. WORDEN
--------------------
 Signature

Andrew Worden, Managing Member of the General Partner of Barron Partners LP